A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer

摘要

Context: Molecular biomarkers aim to address the established limitations of clinicopathologic factors to accurately risk stratify patients with prostate cancer (PCa). Questions remain as to whether sufficient evidence supports adoption of these biomarkers for clinical use.